Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis

• Main Authors: Jacob P. Thyssen (Author), Thomas Bieber (Author), C. Elise Kleyn (Author), Audrey Nosbaum (Author), Susanne Grond (Author), Helmut Petto (Author), Elisabeth Riedl (Author), Andreas Wollenberg (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor approved for moderate-to-severe atopic dermatitis (AD) in adults. Objectives To evaluate absolute Eczema Area and Severity Index (EASI) and SCORing of Atopic Dermatitis (SCORAD) outcomes over 16 weeks and to link disease severity...